CND Life Sciences
SCOTTSDALE, AZ, United States · Biotechnology · 89 employees
CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other conditions. Operating a CLIA-certified laboratory in Scottsdale, AZ, CND launched the Syn-One Test® as the first commercially available test to detect, visualize, and quantify the presence of misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as a
Funding history
- Funding Round — $8.6M — May 2025
- Series seed — $3.5M — Mar 2025
- Series seed — $2.0M — Mar 2024
- Series seed — $1.5M — Jul 2023
- Series seed — Undisclosed — Apr 2023
Recent signals
- May 06, 2025: Raised $8.6M
- Mar 06, 2025: Raised $3.5M in Series seed
- Jun 26, 2024: CND Life Sciences Welcomes Four New Executives to Leadership Team
- Mar 27, 2024: Raised $2.0M in Series seed
- Jul 24, 2023: Raised $1.5M in Series seed
- Apr 06, 2023: Raised funding in Series seed
- Mar 24, 2023: Raised $4.5M in Series seed
- Sep 22, 2022: Raised $2.5M in Series seed
See plans & pricing → Track CND Life Sciences’s funding, hiring, and signals — with verified contacts — on Fundz.